Ardent Health, Inc. 8-K

What Happened Ardent Health, Inc. (ARDT) filed an 8‑K reporting that Martin J. Bonick departed as President and Chief Executive Officer and stepped down from the company’s Board of Directors, effective June 2, 2026. On June 26, 2026 Mr. Bonick and an affiliate of the company (AHS Management Company, Inc.) executed a Separation Agreement and General Release, filed as Exhibit 10.1 to the 8‑K. The separation agreement provides for severance benefits consistent with a termination without “Cause” as described in the company’s Definitive Proxy Statement filed April 8, 2026.

Key Details

• Effective date of departure: June 2, 2026; Separation Agreement dated June 26, 2026; 8‑K filed June 30, 2026.
• Severance treatment: benefits consistent with a termination by the company without “Cause” (specific dollar amounts not disclosed in the 8‑K; see April 8, 2026 Proxy for plan terms).
• Equity treatment: vesting and/or forfeiture of time‑based RSUs, performance‑based RSUs and restricted shares governed by the company’s incentive award plan and the applicable award agreements.
• Restrictions: 12‑month non‑competition and non‑solicitation covenants following the Effective Date; separation subject to non‑revocation and release of claims by Mr. Bonick.

Why It Matters This filing confirms a leadership change at the CEO level and documents the company’s agreed exit terms. For investors, the filing signals potential near‑term impacts on governance and executive transition planning; it also establishes contractual severance and restrictive covenants but does not disclose the cash cost. Investors should review the April 8, 2026 Proxy for the specific severance framework, and watch for subsequent filings naming an interim or new CEO and any related disclosures about compensation expense or strategic changes.